ADC Therapeutics SA
COMBINATION THERAPY
Last updated:
Abstract:
The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an anti-CD19 Antibody Drug Conjugate (anti-CD19 ADC) and an anti-BCL-2 agent.
Status:
Application
Type:
Utility
Filling date:
30 Aug 2019
Issue date:
21 Oct 2021